Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Viatris Inc. (VTRS)

9.86   0.05 (0.51%) 09-29 16:00
Open: 9.84 Pre. Close: 9.81
High: 10.025 Low: 9.84
Volume: 6,051,996 Market Cap: 11,827(M)

Technical analysis

as of: 2023-09-29 4:31:12 PM
Short-term rate:       
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Mid-term rate:       
Target: Six months: 12.25     One year: 12.99
Support: Support1: 9.46    Support2: 7.87
Resistance: Resistance1: 10.49    Resistance2: 11.13
Pivot: 9.78
Moving Average: MA(5): 9.73     MA(20): 9.92
MA(100): 10.09     MA(250): 10.37
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 38.5     %D(3): 26.4
RSI: RSI(14): 41.9
52-week: High: 12.39  Low: 8.46
Average Vol(K): 3-Month: 8,492 (K)  10-Days: 7,910 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ VTRS ] has closed below upper band by 33.3%. Bollinger Bands are 57.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.03 - 10.07 10.07 - 10.12
Low: 9.73 - 9.78 9.78 - 9.82
Close: 9.78 - 9.85 9.85 - 9.93

Company Description

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Headline News

Mon, 02 Oct 2023
Viatris Inc (VTRS) Announces Agreements on Remaining Planned ... -

Sat, 30 Sep 2023
Could Viatris Stock Help You Become a Millionaire? - Nasdaq

Fri, 29 Sep 2023
Is Viatris Inc (VTRS) Stock a Good Value Friday? - InvestorsObserver

Fri, 29 Sep 2023
First Week of April 2024 Options Trading For Viatris (VTRS) - Nasdaq

Thu, 28 Sep 2023
Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent - Nasdaq

Wed, 27 Sep 2023
Viatris Inc [VTRS] Stock trading around $9.72 per share: What's Next ... - The DBT News

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 1,200 (M)
Shares Float 1,190 (M)
% Held by Insiders 0.3 (%)
% Held by Institutions 78.1 (%)
Shares Short 33,560 (K)
Shares Short P.Month 24,350 (K)

Stock Financials

EPS 1.52
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 17.37
Profit Margin (%) 11.8
Operating Margin (%) 14.8
Return on Assets (ttm) 2.9
Return on Equity (ttm) 9.1
Qtrly Rev. Growth -4.9
Gross Profit (p.s.) 5.85
Sales Per Share 13
EBITDA (p.s.) 4.27
Qtrly Earnings Growth -15
Operating Cash Flow 2,500 (M)
Levered Free Cash Flow 4,220 (M)

Stock Valuations

PE Ratio 6.44
PEG Ratio -1.6
Price to Book value 0.56
Price to Sales 0.75
Price to Cash Flow 4.73

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.